This list is based on the watchlists of people on Stock Events who follow REG.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
The current price of REG.STU is €11.35 EUR — it has increased by +0.04% in the past 24 hours. Watch RemeGen. stock price performance more closely on the chart.
What is RemeGen. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange RemeGen. stocks are traded under the ticker REG.STU.
Is RemeGen. stock price growing?▼
REG.STU stock has fallen by -9.96% compared to the previous week, the month change is a +16.36% rise, over the last year RemeGen. has showed a +248.01% increase.
When is the next RemeGen. earnings date?▼
RemeGen. is going to release the next earnings report on August 26, 2026.
How many employees does RemeGen. have?▼
As of April 11, 2026, the company has 3,048 employees.